Castro M, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355-66. ,Marth K, et al. Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria. ERS 2018, Parijs. Sessie 379; OA3568.
128.000 nieuwe kankerpatiënten in 2023: meer diagnoses in vroeg stadium
feb 2024 | Borstkanker, Dermato-oncologie, Gynaecologische oncologie, Hoofd-halsoncologie, Longoncologie, Maag-darm-leveroncologie, Uro-oncologie